Varodayan Florence P, Erikson Chloe M, Scroger Marcis V, Roberto Marisa
Developmental Exposure Alcohol Research Center and Behavioral Neuroscience Program, Department of Psychology, Binghamton University, SUNY, Binghamton, New York.
Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California.
Biol Psychiatry. 2025 Mar 15;97(6):580-589. doi: 10.1016/j.biopsych.2024.09.009. Epub 2024 Sep 18.
Hyperkatifeia, the manifestation of emotional distress or pain, is a conceptual framework gaining traction throughout the alcohol and other substance use fields as an important driver of addiction. It is well known that previous or current negative life experiences can serve as powerful motivators for excessive alcohol consumption and precipitate the development of an alcohol use disorder (AUD). A major hallmark of later stages of AUD is the emergence of hyperkatifeia during withdrawal, which can persist well into protracted abstinence to drive relapse. Given these complex interactions, understanding the specific neuroadaptations that lie at the intersection of hyperkatifeia and AUD can inform ongoing therapeutic development. The monoamine norepinephrine is of particular interest. Noradrenergic dysfunction is implicated in AUD, anxiety, chronic stress, depression, and emotional and physical pain. Importantly, there are key sexual dimorphisms within the noradrenergic system that are thought to differentially impact the development and trajectory of AUD in women and men. In the current review, we discuss past and recent work on noradrenergic influences at each stage of the AUD cycle (binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation) through the lens of hyperkatifeia. Evidence from these studies support the prioritization of norepinephrine-specific drug development to treat AUD and the identification of AUD subpopulations that may benefit the most from these therapies (e.g., women or people with comorbid chronic pain or anxiety/stress disorders).
过度烦躁,即情绪困扰或痛苦的表现,作为成瘾的一个重要驱动因素,是一个在酒精及其他物质使用领域越来越受关注的概念框架。众所周知,既往或当前的负面生活经历可能成为过量饮酒的强大诱因,并促使酒精使用障碍(AUD)的发展。AUD后期的一个主要特征是在戒断期间出现过度烦躁,这种情况可能会持续到长期戒酒阶段,从而导致复吸。鉴于这些复杂的相互作用,了解过度烦躁与AUD交叉点处的特定神经适应性变化,可为正在进行的治疗开发提供信息。单胺类神经递质去甲肾上腺素尤其值得关注。去甲肾上腺素能功能障碍与AUD、焦虑、慢性应激、抑郁以及情绪和身体疼痛有关。重要的是,去甲肾上腺素能系统内存在关键的性别差异,这些差异被认为会对男性和女性AUD的发展和病程产生不同影响。在本综述中,我们将通过过度烦躁这一视角,讨论过去和近期关于去甲肾上腺素能在AUD周期各阶段(暴饮/中毒、戒断/负面影响以及专注/预期)影响的研究。这些研究的证据支持将去甲肾上腺素特异性药物开发作为治疗AUD的优先事项,并确定可能从这些疗法中获益最大的AUD亚群(例如,女性或患有慢性疼痛或焦虑/应激障碍合并症的人)。